Elevated CD38 antigen expression on CD8+ T cells Is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS Cohort study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 16, Issue 2, 1997, Pages 83-92

  Liu, Zhiyuan ^a,d   Cumberland, William G ^a   Hultin, Lance E ^b   Prince, Harry E ^c,e   Detels, Roger ^a   Giorgi, Janis V ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMERICAN RED CROSS BLOOD SERVICES   (United States)

^d Division of Communicable Diseases   (United States)

^e MRL Reference Laboratory   (United States)

Author keywords

CD38 antigen; CD8+ cells; Flow cytometry; Immune activation; Neopterin; Prognostic marker; Quantitative fluorescence; Soluble CD8; Soluble IL 2 receptor; Soluble TNF receptor type II; 2 Microglobulin

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; NEOPTERIN; TUMOR NECROSIS FACTOR RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN EXPRESSION; ARTICLE; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADP-RIBOSYL CYCLASE; ADULT; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, CD8; ANTIGENS, DIFFERENTIATION; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; COHORT STUDIES; DISEASE PROGRESSION; FLOW CYTOMETRY; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-2; MALE; MEMBRANE GLYCOPROTEINS; NAD+ NUCLEOSIDASE; NEOPTERIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK; SURVIVORS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030668834     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199710010-00003     Document Type: Article

References (53)

1. Salazar-Gonzáles JF, Moody DJ, Giorgi JV, Martinez-Maza O, Mitsuyasu RT, Fahey JL. Reduced ecto-5′-nucleotidase activity and enhanced OKT10 and HLA-DR expression on CD8 (T suppressor/cytotoxic) lymphocytes in the acquired immune deficiency syndrome: evidence of CD8 cell immaturity. J Immunol 1985;135: 1778-85.
2. Giorgi JV, Detels R. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS Cohort Study. Clin Immunol Immunopathol 1989;52:10-8.
3. Prince HE, Jensen ER. Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. JAIDS 1991;4:1227-32.
4. + cytotoxic T cells express CD38 and HLA-DR antigens. J. Immunol 1993;150:3070-9.
5. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-10.
6. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68: 4650-5.
7. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
8. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62.
9. + lymphocyte activity. J Infect Dis 1995;172:329-39.
10. + cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 1996;10:F17-F22.
11. Fahey JL, Giorgi J, Martinez-Maza O, Detels R, Mitsuyasu R, Taylor J. Immune pathogenesis of AIDS and related syndromes. Ann Inst Pasteur Immunol 1987;138:245-52.
12. + lymphocytes. J Immunol 1989;142:773-80.
13. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen ISY. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-22.
14. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86:1082-9.
15. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995;182:1727-37.
16. Pantaleo G, Fauci AS. New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 1995;13:487-512.
17. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-30.
18. Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol 1992;90:376-82.
19. + T cell levels: results of 6 years of follow-up. JAIDS 1993;6:904-12.
20. + T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Commun Clin Cytometry 1996;26:1-7.
21. + T cells in HIV-1-infected patients. AIDS 1996;10:827-34.
22. Fuchs D, Jäger H, Popescu M, et al. Immune activation markers to predict AIDS and survival in HIV-1 seropositives. Immunol Lett 1990;26:75-80.
23. Moss AR, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J 1988;296:745-50.
24. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
25. Giorgi JV. CD4 counts in relation to markers of immune activation. In: Janossy G, Autran B, Miedema F, eds. Immunodeficiency in HIV infection and AIDS. Basel: Karger, 1992:1-17.
26. Godfried MH, van der Poll T, Weverling GJ, et al. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994;169:739-45.
27. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987;126:310-8.
28. Detels R, Phair JP, Saah AJ, et al. Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study. J Epidemiol 1992;2:511-9.
29. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS amona adolescents and adults. MMWR 1992; 41(No. RR-17):1-19.
30. Bass HZ, Hardy WD, Mitsuyasu RT, Wang Y-X, Cumberland W. Fahey JL. Eleven lymphoid phenotypic markers in HIV infection: selective changes induced by zidovudine treatment. JAIDS 1992; 5:890-7.
31. Schmid I, Schmid P, Giorgi JV. Conversion of logarithmic channel numbers into relative linear fluorescence intensity. Cytometry 1988;9:533-8.
32. Schenker EL, Hultin LE, Bauer KD, Ferbas J, Margolick JB, Giorgi JV. Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry 1993;14:307-17.
33. Calvelli T, Denny TN, Paxton H, Gelman R, Kagan J. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 1993;14:702-15.
34. Poncelet P, George F, Lavabre-Bertrand T. Immunological detection of membrane-bound antigens and receptors. In: Masseyeff RF, Albert WH, Staines NA, eds. Methods of immunological analysis. Weinheim, Germany: VCH Verlagsgesellschaft mbH, 1993:388-417.
35. Hultin L, Matud J, Giorgi JV. Tight regulation of CD4 antigen expression on lymphocytes of healthy donors used directly as a fluorescence quantitation standard. Cytometry 1996;(Suppl 8):90.
36. + cell levels. J Infect Dis 1994;170:775-81.
37. Cox DR. Regression models and life-tables. J R Stat Soc 1972;34: 187-220.
38. Dixon WJ. BMDP statistical software manual. Los Angeles: University of California Press, 1988.
39. + T cells in HIV disease and following in vitro activation. In: Schlossman SF, Boumsell L, Gilks W, et al. eds. Leucocyte typing V: White cell differentiation antigens, 1st ed. Oxford: Oxford University Press, 1995:446-61.
40. Giorgi JV. Phenotype and function of T cells in HIV disease. In: Gupta S, ed. Immunology of HIV infection. New York: Plenum Press, 1996:181-99.
41. Roederer M, Herzenberg LA, Herzenberg LA. Changes in antigen densities on leukocyte subsets correlate with progression of HIV disease. Int Immunol 1996;8:1-11.
42. Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K. Human CD38: a glycoprotein in search of a function. Immunol Today 1994;15:95-7.
43. Plaeger-Marshall S, Hultin P, Bertolli J, et al. Activation and differentiation antigens on T cells of healthy, at-risk, and HIV-infected children. JAIDS 1993;6:984-93.
44. Hercend T, Ritz J, Schlossman SF, Reinherz EL. Comparative expression of T9, T10, and 1a antigens on activated human T cell subsets. Hum Immunol 1981;3:247-59.
45. Funaro A, Spagnoli GC, Ausiello CM, et al. Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. J Immunol 1990;145:2390-6.
46. Prince HE, Kleinman S, Czaplicki C, John J, Williams AE. Interrelationships between serologic markers of immune activation and T lymphocyte subsets in HIV infection. JAIDS 1990;3:525-30.
47. Deterre P, Gelman L, Gary-Gouy H, et al. Coordinated regulation in human T cells of nucleotide-hydrolyzing ecto-enzymatic activities, including CD38 and PC-1: possible role in the recycling of nicotinamide adenine dinucleotide metabolites. J Immunol 1996; 157:1381-8.
48. Bofill M, Fairbanks LD, Ruckemann K, Lipman M, Simmonds HA. T-lymphocytes from AIDS patients are unable to synthesize ribonucleotides de novo in response to mitogenic stimulation. J Biol Chem 1995;270:29690-7.
49. Prince HE, Jensen ER. HIV-related alterations in CD8 cell subsets defined by in vitro survival characteristics. Cell Immunol 1991; 134:276-86.
50. Howard M, Grimaldi JC, Bazan JF, et al. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science 1993;262:1056-9.
51. Dianzani U, Malavasi F. Lymphocyte adhesion to endothelium. Crit Rev Immunol 1995;15:167-200.
52. Kelleher AD, Zaunders ACJ, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
53. + T cell homeostasis and function in advanced HIV disease. Science 1997;278:112-116.